Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Abroad (travel likely)RecruitingPHASE2
Conditions
Non-Small Cell Lung Cancer · RET Driver Mutation · BRAF V600 Mutation · Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation · MET Amplification · MET Exon 14 Skipping Mutation
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guanzhou, Guangdong, China
Contact: Principal Investigator (Wen-Zhao Zhong, Ph.D)Rui Fu, Ph.D (Sub-investigator)Contact: Principal Investigator (Chao Zhang, Ph.D)